A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-06-13

AUTHORS

Hei-Cheul Jeung, Sun Young Rha, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung

ABSTRACT

PurposeThis study was to evaluate the activity and the safety of a combination chemotherapy regimen of weekly fractionated irinotecan and cisplatin in advanced gastric cancer patients.MethodsPatients with advanced gastric adenocarcinoma with either chemotherapy-naive or only one prior chemotherapy regimen received irinotecan 50 mg/m2 followed by cisplatin 30 mg/m2. Both drugs were administered weekly for 3 consecutive weeks, followed by 1-week rest. Treatment was repeated until disease progression occurred. Response evaluation was performed according to the RECIST criteria.ResultsForty-seven patients (13 chemo-naive, 34 prior chemotherapy) were enrolled. Of 46 evaluable patients, overall response rate was 25.5% (95% CI, 12.9–39.3%) and disease control rate was 63.8% (95% CI, 50.9–79.5%) by intent-to-treat analysis. The time to progression and overall survival duration were 21 and 44 weeks, respectively. One-year survival rate was 41.6%. The most frequent grade 4 toxicity was neutropenia, which was the major cause of treatment delay. Non-hematological toxicities of grade 3–4 were rare with occurrence rate of 14.9% for anorexia and emesis.ConclusionsFractionated irinotecan combined with cisplatin with 3-week-on and 1-week-off schedule produced favorable clinical results for advanced gastric cancer. Because of the feasible efficacy and low non-hematologic toxicity, this treatment could be a promising salvage regimen in patients who have failed to taxanes. More... »

PAGES

313-320

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-006-0272-z

DOI

http://dx.doi.org/10.1007/s00280-006-0272-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014649059

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16770582


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Camptothecin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Irinotecan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outpatients", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stomach Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jeung", 
        "givenName": "Hei-Cheul", 
        "id": "sg:person.01276364570.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276364570.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
            "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rha", 
        "givenName": "Sun Young", 
        "id": "sg:person.01036404665.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036404665.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea", 
            "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noh", 
        "givenName": "Sung Hoon", 
        "id": "sg:person.01120377020.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120377020.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
            "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roh", 
        "givenName": "Jae Kyung", 
        "id": "sg:person.0767622633.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767622633.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
            "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chung", 
        "givenName": "Hyun Cheol", 
        "id": "sg:person.016554426212.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s101470300007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032208652", 
          "https://doi.org/10.1007/s101470300007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1054/bjoc.2000.1631", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020520952", 
          "https://doi.org/10.1054/bjoc.2000.1631"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6690350", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045469768", 
          "https://doi.org/10.1038/sj.bjc.6690350"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-06-13", 
    "datePublishedReg": "2006-06-13", 
    "description": "PurposeThis study was to evaluate the activity and the safety of a combination chemotherapy regimen of weekly fractionated irinotecan and cisplatin in advanced gastric cancer patients.MethodsPatients with advanced gastric adenocarcinoma with either chemotherapy-naive or only one prior chemotherapy regimen received irinotecan 50\u00a0mg/m2 followed by cisplatin 30\u00a0mg/m2. Both drugs were administered weekly for 3 consecutive weeks, followed by 1-week rest. Treatment was repeated until disease progression occurred. Response evaluation was performed according to the RECIST criteria.ResultsForty-seven patients (13 chemo-naive, 34 prior chemotherapy) were enrolled. Of 46 evaluable patients, overall response rate was 25.5% (95% CI, 12.9\u201339.3%) and disease control rate was 63.8% (95% CI, 50.9\u201379.5%) by intent-to-treat analysis. The time to progression and overall survival duration were 21 and 44\u00a0weeks, respectively. One-year survival rate was 41.6%. The most frequent grade 4 toxicity was neutropenia, which was the major cause of treatment delay. Non-hematological toxicities of grade 3\u20134 were rare with occurrence rate of 14.9% for anorexia and emesis.ConclusionsFractionated irinotecan combined with cisplatin with 3-week-on and 1-week-off schedule produced favorable clinical results for advanced gastric cancer. Because of the feasible efficacy and low non-hematologic toxicity, this treatment could be a promising salvage regimen in patients who have failed to taxanes.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-006-0272-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "59"
      }
    ], 
    "keywords": [
      "advanced gastric cancer", 
      "chemotherapy regimen", 
      "gastric cancer", 
      "one-year survival rate", 
      "advanced gastric cancer patients", 
      "prior chemotherapy regimen", 
      "disease control rate", 
      "grade 4 toxicity", 
      "non-hematologic toxicities", 
      "promising salvage regimen", 
      "overall survival duration", 
      "non-hematological toxicities", 
      "combination chemotherapy regimen", 
      "phase II trial", 
      "ResultsForty-seven patients", 
      "favorable clinical results", 
      "gastric cancer patients", 
      "overall response rate", 
      "advanced gastric adenocarcinoma", 
      "cisplatin 30", 
      "evaluable patients", 
      "salvage regimen", 
      "RECIST criteria", 
      "II trial", 
      "treat analysis", 
      "treatment delay", 
      "cancer patients", 
      "control rate", 
      "survival duration", 
      "gastric adenocarcinoma", 
      "disease progression", 
      "clinical results", 
      "feasible efficacy", 
      "grade 3", 
      "response rate", 
      "survival rate", 
      "patients", 
      "consecutive weeks", 
      "PurposeThis study", 
      "regimen", 
      "major cause", 
      "response evaluation", 
      "cisplatin", 
      "cancer", 
      "progression", 
      "weeks", 
      "toxicity", 
      "treatment", 
      "occurrence rate", 
      "MethodsPatients", 
      "neutropenia", 
      "emesis", 
      "adenocarcinoma", 
      "anorexia", 
      "irinotecan", 
      "taxanes", 
      "trials", 
      "drugs", 
      "efficacy", 
      "rate", 
      "m2", 
      "cause", 
      "duration", 
      "safety", 
      "rest", 
      "schedule", 
      "activity", 
      "criteria", 
      "evaluation", 
      "study", 
      "intent", 
      "delay", 
      "time", 
      "analysis", 
      "results"
    ], 
    "name": "A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer", 
    "pagination": "313-320", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014649059"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-006-0272-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16770582"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-006-0272-z", 
      "https://app.dimensions.ai/details/publication/pub.1014649059"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_421.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-006-0272-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0272-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0272-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0272-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0272-z'


 

This table displays all metadata directly associated to this object as RDF triples.

244 TRIPLES      22 PREDICATES      120 URIs      109 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-006-0272-z schema:about N05342c1e23c04dd6b9f460013f253602
2 N108be11bd2ba4e96ac6c54363504e1b6
3 N13dcf0f1cf2943319309c617e7f4aeef
4 N1cd632e41a234a6b893b6da5e535a314
5 N3238239dd4f94093b29e4a28e8e6fb28
6 N32f330d6581d4f76af0b1ea7dff6e0fd
7 N37c02ff78a964a9c92b73e9a982141c3
8 N3bcde05785314b6db6e7f68593ccb830
9 N55fea4089573429b8cd236739c674da4
10 N56058613cdd144d2bd31f6854acb6f43
11 N6079d9e9ea094c7bbf465fbbb5c21d53
12 N682ad4590c1a4c9c9b164afdcaa44003
13 N85a8d33a829b405c984a0508b3400720
14 Nb947ab0785874a6288d54842a08b8b42
15 Nbe8500d930154db58bd24a85dfa41f82
16 Nd888f196cfde43bd8b7318cc02f0fdf0
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N9dc06fab8e3941adb5173e97781296bb
20 schema:citation sg:pub.10.1007/s101470300007
21 sg:pub.10.1038/sj.bjc.6690350
22 sg:pub.10.1054/bjoc.2000.1631
23 schema:datePublished 2006-06-13
24 schema:datePublishedReg 2006-06-13
25 schema:description PurposeThis study was to evaluate the activity and the safety of a combination chemotherapy regimen of weekly fractionated irinotecan and cisplatin in advanced gastric cancer patients.MethodsPatients with advanced gastric adenocarcinoma with either chemotherapy-naive or only one prior chemotherapy regimen received irinotecan 50 mg/m2 followed by cisplatin 30 mg/m2. Both drugs were administered weekly for 3 consecutive weeks, followed by 1-week rest. Treatment was repeated until disease progression occurred. Response evaluation was performed according to the RECIST criteria.ResultsForty-seven patients (13 chemo-naive, 34 prior chemotherapy) were enrolled. Of 46 evaluable patients, overall response rate was 25.5% (95% CI, 12.9–39.3%) and disease control rate was 63.8% (95% CI, 50.9–79.5%) by intent-to-treat analysis. The time to progression and overall survival duration were 21 and 44 weeks, respectively. One-year survival rate was 41.6%. The most frequent grade 4 toxicity was neutropenia, which was the major cause of treatment delay. Non-hematological toxicities of grade 3–4 were rare with occurrence rate of 14.9% for anorexia and emesis.ConclusionsFractionated irinotecan combined with cisplatin with 3-week-on and 1-week-off schedule produced favorable clinical results for advanced gastric cancer. Because of the feasible efficacy and low non-hematologic toxicity, this treatment could be a promising salvage regimen in patients who have failed to taxanes.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N5841e7a17d444c00923d114742899c63
30 Nfdf4660ecdbe471fa2b5ed3b06997492
31 sg:journal.1088364
32 schema:keywords II trial
33 MethodsPatients
34 PurposeThis study
35 RECIST criteria
36 ResultsForty-seven patients
37 activity
38 adenocarcinoma
39 advanced gastric adenocarcinoma
40 advanced gastric cancer
41 advanced gastric cancer patients
42 analysis
43 anorexia
44 cancer
45 cancer patients
46 cause
47 chemotherapy regimen
48 cisplatin
49 cisplatin 30
50 clinical results
51 combination chemotherapy regimen
52 consecutive weeks
53 control rate
54 criteria
55 delay
56 disease control rate
57 disease progression
58 drugs
59 duration
60 efficacy
61 emesis
62 evaluable patients
63 evaluation
64 favorable clinical results
65 feasible efficacy
66 gastric adenocarcinoma
67 gastric cancer
68 gastric cancer patients
69 grade 3
70 grade 4 toxicity
71 intent
72 irinotecan
73 m2
74 major cause
75 neutropenia
76 non-hematologic toxicities
77 non-hematological toxicities
78 occurrence rate
79 one-year survival rate
80 overall response rate
81 overall survival duration
82 patients
83 phase II trial
84 prior chemotherapy regimen
85 progression
86 promising salvage regimen
87 rate
88 regimen
89 response evaluation
90 response rate
91 rest
92 results
93 safety
94 salvage regimen
95 schedule
96 study
97 survival duration
98 survival rate
99 taxanes
100 time
101 toxicity
102 treat analysis
103 treatment
104 treatment delay
105 trials
106 weeks
107 schema:name A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer
108 schema:pagination 313-320
109 schema:productId N185a1a1062a94768853081aab006b1de
110 N3e6c2d9813e04af385e98aea5d48decf
111 Ncd5c01c6ac1e4adcb9d61c85be831928
112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014649059
113 https://doi.org/10.1007/s00280-006-0272-z
114 schema:sdDatePublished 2022-05-20T07:23
115 schema:sdLicense https://scigraph.springernature.com/explorer/license/
116 schema:sdPublisher N026fd4deb8d1407aa819371d2dba0690
117 schema:url https://doi.org/10.1007/s00280-006-0272-z
118 sgo:license sg:explorer/license/
119 sgo:sdDataset articles
120 rdf:type schema:ScholarlyArticle
121 N026fd4deb8d1407aa819371d2dba0690 schema:name Springer Nature - SN SciGraph project
122 rdf:type schema:Organization
123 N05342c1e23c04dd6b9f460013f253602 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Male
125 rdf:type schema:DefinedTerm
126 N108be11bd2ba4e96ac6c54363504e1b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Adenocarcinoma
128 rdf:type schema:DefinedTerm
129 N13dcf0f1cf2943319309c617e7f4aeef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Antineoplastic Combined Chemotherapy Protocols
131 rdf:type schema:DefinedTerm
132 N185a1a1062a94768853081aab006b1de schema:name pubmed_id
133 schema:value 16770582
134 rdf:type schema:PropertyValue
135 N1cd632e41a234a6b893b6da5e535a314 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Outpatients
137 rdf:type schema:DefinedTerm
138 N3238239dd4f94093b29e4a28e8e6fb28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Salvage Therapy
140 rdf:type schema:DefinedTerm
141 N32f330d6581d4f76af0b1ea7dff6e0fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Stomach Neoplasms
143 rdf:type schema:DefinedTerm
144 N35f3478cb3ff403f88d17545f298fc84 rdf:first sg:person.01120377020.04
145 rdf:rest N7ecfd16c9aa4442cb0ca8a96aa0eeafc
146 N37c02ff78a964a9c92b73e9a982141c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Aged
148 rdf:type schema:DefinedTerm
149 N3bcde05785314b6db6e7f68593ccb830 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Middle Aged
151 rdf:type schema:DefinedTerm
152 N3e6c2d9813e04af385e98aea5d48decf schema:name dimensions_id
153 schema:value pub.1014649059
154 rdf:type schema:PropertyValue
155 N53a1164e43174455b15dc72053e5bffa rdf:first sg:person.016554426212.74
156 rdf:rest rdf:nil
157 N55fea4089573429b8cd236739c674da4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Female
159 rdf:type schema:DefinedTerm
160 N56058613cdd144d2bd31f6854acb6f43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Humans
162 rdf:type schema:DefinedTerm
163 N5841e7a17d444c00923d114742899c63 schema:issueNumber 3
164 rdf:type schema:PublicationIssue
165 N6079d9e9ea094c7bbf465fbbb5c21d53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Cisplatin
167 rdf:type schema:DefinedTerm
168 N682ad4590c1a4c9c9b164afdcaa44003 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Drug Administration Schedule
170 rdf:type schema:DefinedTerm
171 N7ecfd16c9aa4442cb0ca8a96aa0eeafc rdf:first sg:person.0767622633.82
172 rdf:rest N53a1164e43174455b15dc72053e5bffa
173 N85a8d33a829b405c984a0508b3400720 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Camptothecin
175 rdf:type schema:DefinedTerm
176 N9dc06fab8e3941adb5173e97781296bb rdf:first sg:person.01276364570.14
177 rdf:rest Nd70e79fe978d44ddb405893f3d50c033
178 Nb947ab0785874a6288d54842a08b8b42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Survival Rate
180 rdf:type schema:DefinedTerm
181 Nbe8500d930154db58bd24a85dfa41f82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Adult
183 rdf:type schema:DefinedTerm
184 Ncd5c01c6ac1e4adcb9d61c85be831928 schema:name doi
185 schema:value 10.1007/s00280-006-0272-z
186 rdf:type schema:PropertyValue
187 Nd70e79fe978d44ddb405893f3d50c033 rdf:first sg:person.01036404665.54
188 rdf:rest N35f3478cb3ff403f88d17545f298fc84
189 Nd888f196cfde43bd8b7318cc02f0fdf0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Irinotecan
191 rdf:type schema:DefinedTerm
192 Nfdf4660ecdbe471fa2b5ed3b06997492 schema:volumeNumber 59
193 rdf:type schema:PublicationVolume
194 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
195 schema:name Medical and Health Sciences
196 rdf:type schema:DefinedTerm
197 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
198 schema:name Oncology and Carcinogenesis
199 rdf:type schema:DefinedTerm
200 sg:journal.1088364 schema:issn 0344-5704
201 1432-0843
202 schema:name Cancer Chemotherapy and Pharmacology
203 schema:publisher Springer Nature
204 rdf:type schema:Periodical
205 sg:person.01036404665.54 schema:affiliation grid-institutes:grid.15444.30
206 schema:familyName Rha
207 schema:givenName Sun Young
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036404665.54
209 rdf:type schema:Person
210 sg:person.01120377020.04 schema:affiliation grid-institutes:grid.15444.30
211 schema:familyName Noh
212 schema:givenName Sung Hoon
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120377020.04
214 rdf:type schema:Person
215 sg:person.01276364570.14 schema:affiliation grid-institutes:grid.15444.30
216 schema:familyName Jeung
217 schema:givenName Hei-Cheul
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276364570.14
219 rdf:type schema:Person
220 sg:person.016554426212.74 schema:affiliation grid-institutes:grid.15444.30
221 schema:familyName Chung
222 schema:givenName Hyun Cheol
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74
224 rdf:type schema:Person
225 sg:person.0767622633.82 schema:affiliation grid-institutes:grid.15444.30
226 schema:familyName Roh
227 schema:givenName Jae Kyung
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767622633.82
229 rdf:type schema:Person
230 sg:pub.10.1007/s101470300007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032208652
231 https://doi.org/10.1007/s101470300007
232 rdf:type schema:CreativeWork
233 sg:pub.10.1038/sj.bjc.6690350 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045469768
234 https://doi.org/10.1038/sj.bjc.6690350
235 rdf:type schema:CreativeWork
236 sg:pub.10.1054/bjoc.2000.1631 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020520952
237 https://doi.org/10.1054/bjoc.2000.1631
238 rdf:type schema:CreativeWork
239 grid-institutes:grid.15444.30 schema:alternateName BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea
240 Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea
241 schema:name BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea
242 Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea
243 Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea
244 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...